We are developing technologies to implement biological assays on microfluidics for point-of-care diagnostic applications. Originally supported by the Swiss Commission for Technology and Innovation (CTI) in partnership with the University Hospital of Basel, this research has now branched out into various directions.
We typically partner with companies and institutions, helping them use our technologies via joint development projects and licensing programs. Our partners are usually from the in vitro diagnostics industry and the semiconductor and MEMS sectors. We also have partners from academic and governmental research institutions within collaborative research projects.
We have pioneered numerous concepts involving capillary phenomena to develop a library of microfluidic functions for implementing biological assays in microfluidics. We have also recently started to integrate solid-state sensors into microfluidics for wearable applications in collaboration with the IBM Watson Research Center in New York.
Our vision is to enable quantitative diagnostics and to connect microfluidic chips to smartphones for fast and convenient analysis of numerous samples. Using smartphones and custom-made peripherals, we recently demonstrated the inclusion of anti-counterfeiting security codes, called “crypto anchors”, in microfluidic devices, a new concept for stop-and-go liquid flow control (“electrogates”), and real-time flow monitoring with sub-nanoliter/second precision.
Furthermore, we believe this technology can generate high-value, critical data for many scenarios involving Watson Health and IBM’s expertise with IT and security platforms.
By devising new biomolecular architectures and implementing them using innovative microfluidic elements, we believe we will be able to realize sequential, amplified biological assays featuring unprecedented performance. The CAPSYS EU project is a collaboration with Prof. Christof Niemeyer of the Karlsruhe Institute of Technology, Germany.
[ More ]